Imatinib-related bone marrow aplasia after complete cytogenetic response in chronic myeloid leukemia

被引：0
|
作者：
Khan, Khurshid Ahmed [1 ]
Junaid, Ayesha [2 ]
Siddiqui, Nauman Saleem
Mukhtar, Khalida [3 ]
Siddiqui, Saleem [3 ]
机构：
[1] Natl Oncol Res Inst, Dept Oncol, Islamabad, Pakistan
[2] Shifa Int Hosp, Dept Pathol, Islamabad, Pakistan
[3] Shifa Int Hosp, Dept Haematol & Oncol, Islamabad, Pakistan
来源：
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN | 2008年 / 18卷 / 03期
关键词：
imatinib; chronic myeloid leukemia; bone marrow aplasia;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Imatinib mesylate is a BCR-ABL tyrosine kinase inhibitor used in the management of chronic myeloid leukemia. It is a safe and well-tolerated agent with a few manageable side effects. We are reporting a case of imatinib-related fatal bone marrow aplasia after complete cytogenetic response.
引用
收藏
页码：176 / 178
页数：3
相关论文
共 50 条
  • [1] Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate
    Espinet, Blanca
    Carla Oliveira, Ana
    Boque, Concepcion
    Domingo, Alicia
    Alonso, Esther
    Sole, Francesc
    HAEMATOLOGICA, 2005, 90 (04) : 556 - 558
  • [2] Imatinib-Induced Bone Marrow Aplasia in Chronic Myelogenous Leukemia
    Dogra, Ratika
    Dogra, Vallabh
    Shelke, Abhay R.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (05)
  • [3] Risk and early cytogenetic response to imatinib and interferon in chronic myeloid leukemia
    Rosti, G
    Trabacchi, E
    Bassi, S
    Bonifazi, F
    De Vivo, A
    Martinelli, G
    Alberti, D
    Fincato, G
    Saglio, G
    Baccarani, M
    HAEMATOLOGICA, 2003, 88 (03) : 256 - 259
  • [4] Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib
    Defina, M.
    Gozzetti, A.
    Rondoni, M.
    Aprile, L.
    Ippoliti, M.
    Chitarrelli, I.
    Lauria, F.
    Bocchia, M.
    LEUKEMIA RESEARCH, 2010, 34 (08) : E215 - E216
  • [5] Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-α
    Branford, Susan
    Hughes, Timothy
    Milner, Alvin
    Koelmeyer, Rachel
    Schwarer, Anthony
    Arthur, Chris
    Filshie, Robin
    Moreton, Susan
    Lynch, Kevin
    Taylor, Kerry
    CANCER, 2007, 110 (04) : 801 - 808
  • [6] Severe persistent marrow aplasia in chronic myeloid leukemia (CML): An unusual complication of imatinib
    Madabhavi, Irappa
    Patel, Apurva
    Anand, Asha
    Panchal, Harsha
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2023, 19 (02) : 335 - 339
  • [7] Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy
    Seiichi Okabe
    Tetsuzo Tauchi
    Yuko Ishii
    Daigo Akahane
    Kousuke Nunoda
    Seiko Honda
    Tomoiku Takaku
    Kazuma Ohyashiki
    International Journal of Hematology, 2007, 85 : 173 - 174
  • [8] Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib
    Roche-Lestienne, C
    Darré, S
    Laï, DL
    Facon, T
    Guilhot, J
    Preudhomme, C
    HAEMATOLOGICA, 2005, 90 (01) : 131 - 133
  • [9] Complete Molecular Response in Chronic Myeloid Leukemia After Six Months of Imatinib: A Single Center Experience
    Saleem, Umera
    Hafeez, Talha
    Raza, Syed Ali
    Tahir, Muhammad
    Khalid, Fatima
    Islam, Muhammad Khurrum
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (04)
  • [10] Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia
    Lokeshwar, N
    Kumar, L
    Kumari, M
    LEUKEMIA & LYMPHOMA, 2005, 46 (05) : 781 - 784
12345